Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors Abstract #2082

Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.
Aim(s): Treatment of well-differentiated lung neuroendocrine tumors is challenging.
Materials and methods: 9 patients (median age 62 years, 5 male, 4 female) with advanced well-differentiated (G1-2) lung neuroendocrine tumors with progressive disease treated with EVE.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anna Kuznetsova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors
Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Msc Catharina M Korse
#350 RAD001 and Octreotide LAR as first-line treatment of well differentiated neuroendocrine tumors: an I.T.M.O. (Italian Trials in Medical Oncology) group study
Introduction: RAD001 has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with somatostatine analogues.
Conference:
Category: Basic
Presenting Author: Dr Laura Catena
#383 Everolimus and Octreotide LAR in Neuroendocrine Tumors: An I.T.M.O. (Italian Trials in Medical Oncology) Group Study
Introduction: Everolimus has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with octreotide.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Emilio Bajetta
#451 Symptomatic Control of Neuroendocrine Tumors with Everolimus
Introduction: Everolimus prolongs progression-free survival, but previous research has not demonstrated its effect on symptoms.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Hannah Bainbridge
Authors: Bainbridge H, Larbi E, Middleton G, ...
#474 Difficulties in Diagnosis and Management of Neuroendocrine Tumors of the Head and Neck: A Case Report
Introduction: Primary neuroendocrine carcinomas (NEC) are uncommon head and neck malignancies. They present with a varied histopathologic spectrum in sinonasal and other subsites.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Alla Markovich
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.